Objectives: To assess efficacy and safety of noninvasive ventilation-plus-extracorporeal Co 2 removal in comparison to noninvasive ventilation-only to prevent endotracheal intubation patients with acute hypercapnic respiratory failure at risk of failing noninvasive ventilation. Design: Matched cohort study with historical control.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (http://journals.lww.com/ccmjournal). Key Words: acute hypercapnic respiratory failure; chronic obstructive pulmonary disease; extracorporeal Co 2 removal; mechanical ventilation; noninvasive ventilation; respiratory acidosis N oninvasive ventilation (NIV) represents the standard of care for patients with exacerbation of chronic obstructive pulmonary disease (COPD) who need admission to the ICU for management of acute hypercapnic respiratory failure and severe respiratory acidosis (1) . NIV fails in almost 40% of the most severe forms of acute hypercapnic respiratory failure, and patients must undergo endotracheal intubation and invasive ventilation to restore adequate gas exchange (2) (3) (4) . Patients requiring transition from NIV to invasive ventilation have greater odds of death compared with patients successfully treated with NIV alone (5) .
The clinical efficacy of NIV is based on its ability to wash out the excessive Co 2 by increasing alveolar ventilation (6) . Extracorporeal circuits designed to remove Co 2 (extracorporeal Co 2 removal [ECCO 2 R]) have been used in patients with acute hypercapnic respiratory failure (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) since ECCO 2 R should enhance the efficacy of NIV to remove Co 2 (8, 10, 16, 20) and avoid the worsening of respiratory acidosis (4, 21) . Although available studies are limited to description of single cases (11) (12) (13) (14) (15) or to case series (7) (8) (9) (10) and comparison between "NIV-plus-ECCO 2 R" and "NIV-only" in patients at risk of NIV failure is not available, several ECCO 2 R devices have been developed and proposed for patients with COPD (Maquet PULP: Available at: http://www.maquet.com; Novalung iLA active: Available at: http://www.novalung.com; Alung, Hemolung®RAS: Available at: http://www.alung.com; Hemodec, Decap: Available at: http://www.hemodec.com; Bellco, Abylcap: Available at: http:// www.bellco.net).
The present study estimates the efficacy and safety of ECCO 2 R in association to NIV to reduce need of endotracheal intubation in hypercapnic patients at risk of NIV failure. Since need of intubation for NIV failure progressively decreased (1), patients included in the present study may not represent hypercapnic patients commonly treated with NIV, and the proposed indication for ECCO 2 R may be a niche.
METHODS
We enrolled patients older than 18 and younger than 90 years treated with NIV for acute hypercapnic respiratory failure due to exacerbation of COPD in two Italian ICUs (May 2011 to November 2013). Review boards approved the protocol, and patients provided written consent.
NIV-Plus-ECCO 2 R
Patients with COPD exacerbation and treated with NIV for acute hypercapnic respiratory failure were included. ECCo 2 R was added to NIV in patients who were considered as being "at risk of failure of NIV" when, after at least 2 hours of continuous application of NIV, arterial pH was less than or equal to 7.30 with a PaCo 2 greater than 20% of the baseline value and one of the following was observed: respiratory rate greater than or equal to 30 breaths/ min and use of accessory muscles or paradoxical abdominal movements (4) . Exclusion criteria were as follows: mean arterial pressure less than 60 mm Hg despite infusion of fluids and vasoactive drugs; contraindications to anticoagulation (i.e., any of the following: platelet count < 30,000/mm 3 ; prothrombin time-international normalized ratio > 1.5); stroke or severe head trauma or intracranial arteriovenous malformation, or cerebral aneurysm, or CNS mass lesion within the previous 3 months; epidural catheter in place or expected to be positioned during the study; history of congenital bleeding diatheses; gastrointestinal bleeding within the 6 weeks prior to study entry; esophageal varices, chronic jaundice, cirrhosis, or chronic ascites; trauma; body weight greater than 120 kg; contraindication to continuation of active treatment; and failure to obtain consent. The institutional ethics committee approved collection and report of data at ICU admission and hospital release of patients that did not provide consent to treatment with ECCo 2 R use.
An ECCo 2 R device based on a modified continuous venovenous hemofiltration system (Decap Smart, Hemodec, Salerno, Italy) was used (22 ; maximum blood flow rate, 7 L/min) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 L/min. Exiting the oxygenator, blood is driven to a hemofilter (Medica D250, Medolla, Italy). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 mL/min). A starting dose of heparin (80 IU/kg bolus and 18 IU/kg/hr infusion) was delivered by using a syringe pump included in the system. Continuous infusion of heparin was hence titrated to maintain the activated partial thromboplastin time (aPTT) ratio to approximately 1.5 and checked approximately every 2-3 hours. The femoral vein was accessed via a double-lumen catheter (14F; Joline GmbH & Co. KG, Hechingen, Germany) (22) . ECCO 2 R was interrupted and patients reverted to the "NIVonly" treatment when all of the following were achieved for at least 12 hours: respiratory rate less than 25 breaths/min; pH greater than 7.35; PaCo 2 less than 20% of the baseline value; and absence of use of the accessory muscles or paradoxical abdominal movements.
NIV-Only
A dataset for matched cohort analysis was created using patients treated with "NIV-only" for COPD and acute hypercapnic respiratory failure enrolled in two previous studies performed in the same institutions where the present investigation was carried out (23, 24) . Patients were considered for matching if "at risk of failure on NIV" using the same criteria as for the "NIV-plus-ECCo 2 R" group (4). Exclusion criteria were the same as for the "NIV-plus-ECCo 2 R" group.
Study Endpoints
Primary endpoint was the cumulative prevalence of endotracheal intubation during the 28 days after ICU admission. Decision to intubate was taken by the attending clinicians not involved in the study when two of the following occurred for at least 2 hours: respiratory frequency greater than 35 breaths/ min; arterial pH less than 7.25; PaCo 2 greater than 60 mm Hg; Pao 2 less than 60 mm Hg with an FIo 2 greater than 60%; respiratory arrest; and signs of patient distress with accessory muscle recruitment and paradoxical abdominal or thoracic motion. In addition, intubation was performed when any of the following was observed (6): hemodynamic instability defined as 80-90 mm Hg increase or a 30-40 mm Hg decrease in systolic blood pressure relative to the baseline value or need for inotropic drugs to maintain systolic blood pressure higher than 85 mm Hg or electrocardiogram evidence of ischemia or significant ventricular arrhythmias; need for sedation for major agitation; decreased alertness defined as a Glasgow Coma Score less than 9; and cardiac arrest (6, (23) (24) (25) (26) . Patients were followed up until hospital discharge or death. Secondary endpoints were in-hospital mortality and ICU and hospital length of stay.
Potential adverse events related to ECCO 2 R were recorded and classified as mechanical (membrane lung failure, clots/air in the circuit, pump malfunction, tubing rupture, catheter displacement, and system leaks) and patient-related (vein perforation at cannula insertion, significant bleeding [i.e., any bleeding event that required the administration of 1 U of packed red cells], hemodynamic instability [i.e., 80-90 mm Hg increase or 30-40 mm Hg decrease in systolic blood pressure relative to the baseline value or need for inotropic drugs for at least 2 hr to maintain systolic blood pressure higher than 85 mm Hg or electrocardiogram evidence of ischemia or significant ventricular arrhythmias], ischemic/gangrenous bowel, pneumothorax, renal complications [i.e., occurrence after initiation of Co 2 removal of creatinine > 1.5 mg/dL], infectious complications [i.e., occurrence after initiation of Co 2 removal of culture-proven new infection], metabolic complications [i.e., occurrence after initiation of Co 2 removal of glucose of at least 240 mg/dL or hyperbilirubinemia], thromboembolic complications [i.e., occurrence after initiation of deep venous thrombosis or pulmonary embolus], and neurologic complications [i.e., occurrence after initiation of Co 2 removal of cerebral infarction, or clinical seizure, or cerebral hemorrhage or cerebral edema]) (22) .
Statistical Analysis
The propensity score of receiving ECCo 2 R, that is, the subject's probability of receiving the study treatment conditionally to a number of observed covariates presumed to be associated with the decision to use ECCo 2 R was assessed using a multivariable logistic regression analysis with ECCo 2 R treatment as the dependent variable. The a priori selected variables (4, 21) were age; forced expiratory volume in the 1st second (FEV 1 ); Charlson comorbidity index (27) ; Simplified Acute Physiology Score (SAPS) II (28) ; and value of pH before institution of mechanical ventilation. Except for FEV 1 (taken from the most recent pulmonary function test), all variables were obtained at ICU admission.
The genetic matching method without replacement (GenMatch) was used to match patients treated with "NIV-plusECCo 2 R" and "NIV-only" (29, 30) . GenMatch is a multivariate matching technique that aims to make the distribution of baseline characteristics between "control" and "intervention" as similar as possible combining propensity score matching with multivariate matching. The automated search algorithm makes the multivariate distribution of covariates in the matched "control" and "intervention" groups as similar as possible by estimating the relative weight of the propensity score and of the selected individual; iteratively checking the balance and directing the search toward matches that optimize balance; selecting those weights that give the best covariate balance in the matched samples (29, 30) . The balance statistics was performed using the Wilcoxon-Mann-Whitney test (29, 30) .
To ascertain whether inclusion criteria influenced the basecase findings, all analyses were repeated eliminating from both groups patients with severe neurological impairment (Kelly score ≥ 3) and patients with severe hypoxemia (Pao 2 /FIo 2 < 150) since both are associated to high risk of failure of NIV (4, 21) .
Data are presented as mean (sd) or median (interquartile range). Comparison between and within groups was made using the Wilcoxon-Mann-Whitney test for continuous variables and the chi-square or the Fisher exact test for categorical variables. Results are reported as hazard ratio (HR) with 95% CIs. Cumulative prevalence of endotracheal intubation during the 28 days immediately after ICU admission was assessed considering death as a competing event using the method of Gooley. Adjusted HR and 95% CI were estimated using the Fine and Grey model.
All statistical tests were two-sided and p values of 0.05 or less were considered statistically significant and were conducted using the following software packages: Stata (StataCorp, College Station, TX), R (R Foundation for Statistical Computing, http://www.r-project.org/), and SAS (SAS Institute, Cary, NC).
RESULTS
Two hundred patients with acute hypercapnic respiratory failure due to exacerbation of COPD were admitted for treatment with NIV. Of the 89 patients that matched criteria for being at risk of intubation for NIV failure, 25 patients were treated with "NIV-plus-ECCo 2 R." The remaining 64 patients were not included for the following reasons: mean arterial pressure less than 60 mm Hg despite infusion of fluids and vasoactive drugs (n = 2), contraindications to anticoagulation (n = 4), body weight greater than 120 kg (n = 4), contraindication to continuation of active treatment (n = 13), and failure to obtain consent (n = 41). Of the 198 COPD patients with acute hypercapnic respiratory failure treated with "NIV-only" and previously enrolled (23, 24) , 105 patients met inclusion criteria for being at risk of intubation for NIV failure and 84 patients were eligible for GenMatch analysis. The remaining 21 patients were not included for the following reasons: mean arterial pressure less than 60 mm Hg despite infusion of fluids and vasoactive drugs (n = 6), contraindications to anticoagulation (n = 4), body weight greater than 120 kg (n = 3), and contraindication to continuation of active treatment (n = 8). The GenMatch procedure identified 21 patients from the "NIV-only" group to be compared with the 25 patients of the "NIV-plus-ECCo 2 R" group (Fig. 1) .
Before matching, age and SAPS II score were higher and Charlson comorbidity index was lower in "NIV-only" than in "NIV-plus-ECCo 2 R" (p = 0.0482, 0.0025, and 0.0112, respectively). After matching, there was no difference in baseline characteristics between "NIV-plus-ECCo 2 R" and "NIV-only" groups ( Table 1) . Characteristics of patients at risk of NIV failure but not included in the study protocol (64 patients for the "NIV-plus-ECCo 2 R" group and 21 patients for the "NIV-only" group) did not differ from those included in the final analysis (data presented in the online data supplement, Supplemental Digital Content 1, http://links.lww.com/CCM/B63).
A significant reduction of PaCo 2 from baseline (p = 0.0037) and an increase in arterial pH (p < 0.0001) were observed after 1 hour of treatment only in patients treated with "NIV-plusECCo 2 R" ( Table 2 ). The reduction in respiratory rate after 1 hour of treatment was larger in "NIV-plus-ECCo 2 R" than in "NIV-only" (31% ± 20% vs 11% ± 17% before and after, respectively; p = 0.01). Figure 2 shows the cumulative prevalence of endotracheal intubation in "NIV-plus-ECCo 2 R" and "NIV-only." Application of ECCO 2 R during NIV decreased risk of intubation relative to "NIV-only" by 73% (HR, 0.27; 95% CI, 0.07-0.98; p = 0.047). Intubation rate in the "NIV-plus-ECCo 2 R" group was 12% (three patients; 95% CI, 2.5-31.2), whereas in "NIV-only" was 33% (seven patients; 95% CI, 14.6-57.0; p = 0.1495). Analysis was repeated eliminating patients with severe hypoxemia (Pao 2 /FIo 2 < 150) and patients with severe neurological impairment (Kelly score ≥ 3). In patients without severe hypoxemia, intubation was observed in two out of 22 patients (9%; 95% CI, 1.1-29.2) in "NIV-plus-ECCo 2 R" and in seven out of 17 patients (41%; 95% CI, 18.4-67.0) in "NIVonly" (p = 0.0262). In patients without severe neurological impairment, intubation was observed in 1 out of 16 patients (6%; 95% CI, 0.2-30.2) in "NIV-plus-ECCo 2 R" and in six out of 13 patients (46%; 95% CI, 19.2-74.9) in "NIV-only" (p = 0.026) (Fig. 3) . Indications and timing of intubation are presented in the Online data supplement (Supplemental Digital Content 1, http://links.lww.com/CCM/B63).
Hospital mortality was significantly (p < 0.05) lower in "NIV-plus-ECCo 2 R" than in "NIV-only" (8% [95% CI, 1.0-26.0] vs 33% [95% CI, 18.0-57.5], respectively) ( Table 3) .
Data of the "NIV-only" group before matching are presented in the online data supplement (Supplemental Digital Content 1, http://links.lww.com/CCM/B63).
Thirteen patients (52%) experienced adverse events related to ECCO 2 R ( Table 4 ). All endotracheal intubations observed were due to ECCO 2 R-related adverse events. Patient 4 received invasive mechanical ventilation for severe hemodynamic instability consequent to retroperitoneal bleeding. In patients 14 and 19, clots in the circuit caused interruption of ECCo 2 R with consequent severe respiratory acidosis that required endotracheal intubation.
The use of ECCO 2 R ranged between 24 and 41 hours. Blood flow through the extracorporeal circuit ranged between 177 
DISCUSSION
Recent preliminary reports (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) have described the use of ECCO 2 R in patients with COPD fostering the concept that extracorporeal support in patients with hypercapnic respiratory failure may improve outcome (17, 19, 20) data show that hazard of being intubated was three times higher in patients treated with "NIV-only" than in patients treated with "NIV-plus-ECCo 2 R." However, although intubation rate in "NIV-plus-ECCo 2 R" was lower than "NIV-only," the difference was not statistically significant. These data, and the fact that ECCO 2 R-related complications were observed in almost half of the patients, leave open to future randomized clinical trials the question whether patients with respiratory acidosis refractory to NIV should be intubated and take the risks associated with invasive mechanical ventilation, or should be connected to ECCO 2 R to avoid intubation, but run the risk of the potentially serious ECCO 2 R-related complication. Use of NIV improves outcome in patients with acute hypercapnic respiratory failure (21) . Patients who fail NIV and need endotracheal intubation have a higher odds of death than patients who are successfully treated with NIV (5). In patients with pH less than 7.30, prevalence of NIV failure ranges between 26% (6) and 52% (3) . In the present study, patients included in the "NIV-plus-ECCo 2 R" and "NIV-only" groups were at high risk of failing NIV since they all had severe respiratory acidosis and high respiratory rate that did not improve with NIV (4). In the "NIV-only" group, intubation rate was 48%. This value is consistent with predictive models (4) and previous studies (2, 3) . In the "NIV-plus-ECCo 2 R" treated group, we observed a 73% risk reduction of intubation that could be attributed to the observed increase in arterial pH, decrease in PaCo 2 , and more enhanced reduction of respiratory rate (Table 2 ). In fact, failure of NIV is associated to no improvement of pH and respiratory rate with ventilatory support (4, 21) .
The strength of this study lies in the homogeneity of the patients and the robustness of the matching method used. First, we included patients with a priori identified characteristics that are able to describe general conditions (age and comorbidities) and severity of the impairment of respiratory function (FEV 1 ) and acute critical illness (SAPS II) and are all associated to the risk of failing NIV (1). Furthermore, we excluded those patients in whom ECCO 2 R would have been hard to be implemented (mean arterial pressure < 60 mm Hg, body weight > 120 kg) or not recommended (risk of bleeding or contraindication to continuation of active treatment) (18) . Furthermore, to ascertain whether inclusion criteria influenced the base-case findings, we validated our results adding severe hypoxemia (Pao 2 /FIo 2 < 150) and severe neurological impairment (Kelly score ≥ 3) as alternative exclusion criteria (30) . Second, to match "NIV-plus-ECCo 2 R" with "NIV-only" we used the GenMatch technique, a multivariate matching method that combines propensity score matching with multivariate matching (29) (30) (31) . GenMatch creates matched clusters of data using an automated evolutionary search algorithm that weights the propensity score and each baseline covariate included in the matching and iteratively directs the search toward the matches that maximizes the balance of the covariates included in the analysis (i.e., makes the multivariate distribution of covariates in the matched "control" and "intervention" groups as similar as possible) (29) (30) (31) . GenMatch does not drop observations that cannot be exactly matched but seeks to make the multivariate distribution of covariates in the matched groups as similar as possible and thus avoids the manual process of checking covariate balance in the matched samples and then respecifying the propensity score accordingly (29) (30) (31) . In comparison to propensity score matching, GenMatch achieves the best covariate balance (32) and minimizes bias related to data replacement or arbitrary caliper matching (33) .
Caution must be exercised in generalizing results of the present study. First, institutional review boards refused to authorize a randomized clinical trial due to the limited amount of information regarding the use of ECCo 2 R in patients with COPD. The high number of patients who refused consent to "NIV-plus-ECCo 2 R" confirms the lack of equipoise existing at the moment the study was performed (34) . Although appropriate design of matched cohort study may minimize the risk of systematic overestimation of the magnitude of the treatment, the nonrandomized design remains the major limitation of the present study (35) . To minimize overestimation of the treatment effect, decision to intubate was taken by clinicians not involved in the study using predefined criteria that were 1) objective; 2) coherent with those implemented in the previous studies used to create the dataset for matched cohort analysis (23, 24) ; and 3) consistent with the current literature (6, 25, 26) . However, since severe hypercapnia and respiratory acidosis were the most common indications for intubation (see Online data supplement, Supplemental Digital Content 1, http://links.lww.com/CCM/B63), the use of a surrogate marker of outcome that is directly influenced by the intervention (i.e., Co 2 removal) may confound interpretation of our results. Furthermore, the decisions for intubation may be biased since application of ECCO 2 R was unblinded. The observation of a survival benefit following use of ECCO 2 R suggests that mortality should be the outcome variable of future randomized clinical trials. Second, 13 patients (52%) experienced adverse events associated to the use of ECCO 2 R. Major bleeding episodes were observed in three patients, and one patient experienced vein perforation at cannula insertion. Malfunctioning of the system caused all other adverse events. These side effects of ECCO 2 R should not have impact on clinical outcomes, since hospital mortality was lower in "NIV-plus-ECCo 2 R" than in the "NIVonly." Third, we could have included patients with COPD who are not representative of those commonly admitted to the ICU for treatment with NIV as the rate of intubation and in-hospital mortality in our dataset were significantly higher than those normally observed (1). Fourth, this study is lacking long-term outcome of patients treated with "NIV-plus-ECCo 2 R."
This study first provides a systematic evaluation of the riskbenefit profile of ECCO 2 R in comparison with a control group of patients with COPD at high risk of NIV failure. Results of the present investigation provide the rationale for the future randomized clinical trials that are required to validate the use of ECCO 2 R in patients with hypercapnic respiratory failure and respiratory acidosis nonresponsive to NIV. The observation that the reduction in intubation rate was concomitant to an almost 50% prevalence of ECCO 2 R-related side effects may suggest that primary endpoint of future randomized clinical trials should be long-term mortality rather than intubation rate.
